Merit Medical Systems (MMSI) 주식 개요
는 미국, 중국, 일본, 독일, 프랑스, 영국 및 전 세계에서 중재, 진단 및 치료 절차를 위한 일회용 의료 제품을 설계, 개발, 제조 및 판매하는 회사입니다. 자세히 보기
강점
위험 분석
MMSI가 우리의 위험 점검을 통과했습니다.
MMSI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Merit Medical Systems, Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$73.11 |
| 52주 최고가 | US$94.75 |
| 52주 최저가 | US$59.74 |
| 베타 | 0.51 |
| 1개월 변동 | 9.94% |
| 3개월 변동 | 6.56% |
| 1년 변동 | -14.05% |
| 3년 변동 | 0.84% |
| 5년 변동 | 12.29% |
| IPO 이후 변동 | 1,310.26% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Jul 03
MMSI: Lower P/E Assumptions Will Set Up Future Repricing Potential
The analyst price target for Merit Medical Systems has been reduced from about $118 to $110 as analysts incorporate a slightly lower assumed future P/E multiple, while maintaining modestly higher revenue growth and profit margin assumptions. Analyst Commentary Recent Street research on Merit Medical Systems has centered on lower price targets, but many reports still highlight constructive views on the company’s execution and long term opportunity set.
내러티브 업데이트 • Jun 19
MMSI: Discount Rate Reset And 2026 Guidance Will Support Share Price
Analysts have trimmed their price targets on Merit Medical Systems by between $2 and $20, with the updated fair value estimate holding near $89.55 as they adjust assumptions around discount rates and valuation multiples while keeping revenue growth and profit margin expectations broadly unchanged. Analyst Commentary Recent Street research around Merit Medical Systems shows a cluster of reduced price targets, but the commentary behind those changes is more mixed.내러티브 업데이트 • Jun 04
MMSI: Margin Strength And 2026 Guidance Reset Will Drive Future Upside
Merit Medical Systems' analyst price target has been reset lower by about $8.82 per share. This change reflects analysts' updated assumptions for slightly softer revenue growth, a modestly lower discount rate, stronger profit margins, and a reduced future P/E multiple.Recent updates
내러티브 업데이트 • Jul 03
MMSI: Lower P/E Assumptions Will Set Up Future Repricing Potential
The analyst price target for Merit Medical Systems has been reduced from about $118 to $110 as analysts incorporate a slightly lower assumed future P/E multiple, while maintaining modestly higher revenue growth and profit margin assumptions. Analyst Commentary Recent Street research on Merit Medical Systems has centered on lower price targets, but many reports still highlight constructive views on the company’s execution and long term opportunity set.내러티브 업데이트 • Jun 19
MMSI: Discount Rate Reset And 2026 Guidance Will Support Share Price
Analysts have trimmed their price targets on Merit Medical Systems by between $2 and $20, with the updated fair value estimate holding near $89.55 as they adjust assumptions around discount rates and valuation multiples while keeping revenue growth and profit margin expectations broadly unchanged. Analyst Commentary Recent Street research around Merit Medical Systems shows a cluster of reduced price targets, but the commentary behind those changes is more mixed.내러티브 업데이트 • Jun 04
MMSI: Margin Strength And 2026 Guidance Reset Will Drive Future Upside
Merit Medical Systems' analyst price target has been reset lower by about $8.82 per share. This change reflects analysts' updated assumptions for slightly softer revenue growth, a modestly lower discount rate, stronger profit margins, and a reduced future P/E multiple.새로운 내러티브 • May 16
Oncology And Endoscopy Platforms Will Reshape Long Term Earnings Power
Catalysts About Merit Medical Systems Merit Medical Systems develops and sells medical devices used in vascular, oncology, cardiac, renal and endoscopy procedures worldwide. What are the underlying business or industry changes driving this perspective?Seeking Alpha • May 02
Merit Medical Systems: Creating More Growth Engines (Rating Upgrade)
Summary Merit Medical Systems trades at 17-18x earnings with solid fundamentals, moderate leverage, and reasonable valuation, supporting an upbeat outlook. Q1 organic growth was on the lower end, but full-year guidance was maintained and even slightly raised for sales, reflecting recent M&A contributions. Growth engines include the View Point Medical acquisition and WRAPSODY, both expected to accelerate revenue and margin expansion into 2026. Despite softer organic growth and CEO transition, Merit's business remains resilient, with potential for re-rating as growth drivers materialize. Read the full article on Seeking Alpha
새로운 내러티브 • May 01
Tariffs And OEM Volatility Will Pressure Margins Yet Long Term Procedure Demand Will Support Progress
Catalysts About Merit Medical Systems Merit Medical Systems develops and sells medical devices used in vascular, oncology, cardiac, renal and endoscopy procedures worldwide. What are the underlying business or industry changes driving this perspective?내러티브 업데이트 • Apr 24
MMSI: 2026 Guidance Execution And Margin Resilience Will Drive Future Upside
Analysts have nudged their price targets on Merit Medical slightly lower, with the updated fair value estimate moving from about $101.18 to $98.36 as they factor in modestly softer profit margin assumptions and a somewhat higher future P/E multiple, alongside recent target cuts and a downgrade tied to 2026 guidance uncertainty. Analyst Commentary Recent research on Merit Medical Systems highlights a mix of confidence in the business model and caution around execution against medium term targets, especially the 2026 outlook.내러티브 업데이트 • Apr 08
MMSI: 2026 Margin Outlook And Guidance Will Drive Upside Potential
Analysts have trimmed the blended fair value estimate for Merit Medical Systems to about $101 from roughly $104, reflecting a lower projected price target that incorporates higher discount rates, slightly softer revenue growth assumptions, and a more moderate future P/E multiple, even as margin expectations improve. Analyst Commentary Recent Street research on Merit Medical Systems presents a mixed picture, with some analysts trimming targets or ratings on guidance uncertainty, while others still see room for valuation support based on execution and margins.분석 기사 • Dec 31
We Like These Underlying Return On Capital Trends At Merit Medical Systems (NASDAQ:MMSI)
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...분석 기사 • Jul 14
Calculating The Fair Value Of Merit Medical Systems, Inc. (NASDAQ:MMSI)
Key Insights The projected fair value for Merit Medical Systems is US$80.02 based on 2 Stage Free Cash Flow to Equity...분석 기사 • Jun 29
If EPS Growth Is Important To You, Merit Medical Systems (NASDAQ:MMSI) Presents An Opportunity
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...분석 기사 • May 21
Risks To Shareholder Returns Are Elevated At These Prices For Merit Medical Systems, Inc. (NASDAQ:MMSI)
With a price-to-earnings (or "P/E") ratio of 47.8x Merit Medical Systems, Inc. ( NASDAQ:MMSI ) may be sending very...분석 기사 • May 07
We Take A Look At Why Merit Medical Systems, Inc.'s (NASDAQ:MMSI) CEO Has Earned Their Pay Packet
Key Insights Merit Medical Systems will host its Annual General Meeting on 14th of May CEO Fred Lampropoulos' total...분석 기사 • Apr 11
Merit Medical Systems' (NASDAQ:MMSI) Returns On Capital Are Heading Higher
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? One common approach...분석 기사 • Mar 30
Is Now An Opportune Moment To Examine Merit Medical Systems, Inc. (NASDAQ:MMSI)?
While Merit Medical Systems, Inc. ( NASDAQ:MMSI ) might not have the largest market cap around , it received a lot of...분석 기사 • Mar 18
Here's Why We Think Merit Medical Systems (NASDAQ:MMSI) Is Well Worth Watching
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Seeking Alpha • Mar 16
Merit Medical: A Success Story That Keeps Getting Better
Summary Merit Medical continues to outperform, with the share price supported by on-target financial results, incremental M&A, and positive clinical data. The company's Wrapsody stent graft showed almost best-case clinical efficacy, positioning it to capture significant market share in dialysis graft occlusion procedures. Recent acquisitions, including EsophyX Z+ and Cook Medical’s lead management portfolio, enhance Merit’s product portfolio and offer longer-term synergies. CEO succession remains a concern, but could also prompt a bid for the company. Despite not being "super cheap", Merit’s strong execution, revenue growth, and margin leverage justify a positive rating, with potential for further valuation uplift. Read the full article on Seeking Alpha분석 기사 • Mar 06
A Look At The Fair Value Of Merit Medical Systems, Inc. (NASDAQ:MMSI)
Key Insights Merit Medical Systems' estimated fair value is US$100 based on 2 Stage Free Cash Flow to Equity With...분석 기사 • Feb 10
Merit Medical Systems (NASDAQ:MMSI) Seems To Use Debt Rather Sparingly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...분석 기사 • Jan 17
Why We're Not Concerned About Merit Medical Systems, Inc.'s (NASDAQ:MMSI) Share Price
With a price-to-earnings (or "P/E") ratio of 49.6x Merit Medical Systems, Inc. ( NASDAQ:MMSI ) may be sending very...Seeking Alpha • Jan 08
Merit Medical Systems: Solid Execution, Stretched Valuations
Summary Merit Medical Systems' stock is up 40% from last spring's lows, driven by strong Q3 results and positive analyst sentiment. The stock's rally has stalled recently. The company has also made a small acquisition in September and garnered a key FDA approval to close out 2024 on a high note. More upside ahead, or will the shares experience further profit-taking? An analysis of Merit Medical Systems follows in the paragraphs below. Read the full article on Seeking Alpha분석 기사 • Dec 23
Returns Are Gaining Momentum At Merit Medical Systems (NASDAQ:MMSI)
What are the early trends we should look for to identify a stock that could multiply in value over the long term...분석 기사 • Dec 11
Is Now An Opportune Moment To Examine Merit Medical Systems, Inc. (NASDAQ:MMSI)?
While Merit Medical Systems, Inc. ( NASDAQ:MMSI ) might not have the largest market cap around , it saw a decent share...분석 기사 • Nov 29
Is Now The Time To Put Merit Medical Systems (NASDAQ:MMSI) On Your Watchlist?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...분석 기사 • Nov 02
Merit Medical Systems, Inc. (NASDAQ:MMSI) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
It's been a good week for Merit Medical Systems, Inc. ( NASDAQ:MMSI ) shareholders, because the company has just...분석 기사 • Nov 01
Is Merit Medical Systems (NASDAQ:MMSI) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Sep 17
Merit Medical Systems - Impressive Momentum
Summary Merit Medical Systems has shown strong operating momentum this year, driven by organic growth and strategic acquisitions. Founder Fred Lampropoulos plans to retire by the end of 2025, as a well-planned succession alleviates concerns on that front. Recent acquisitions, including EndoGastric Solutions and Cook's Medical portfolio, enhance product offerings but are priced into the current high valuation. Despite positive momentum and trial results, the stock's high valuation warrants a cautious, wait-and-see approach. Read the full article on Seeking Alpha분석 기사 • Sep 17
The Price Is Right For Merit Medical Systems, Inc. (NASDAQ:MMSI)
Merit Medical Systems, Inc.'s ( NASDAQ:MMSI ) price-to-earnings (or "P/E") ratio of 49.4x might make it look like a...주주 수익률
| MMSI | US Medical Equipment | US 시장 | |
|---|---|---|---|
| 7D | 0.1% | -1.0% | -1.4% |
| 1Y | -14.0% | -21.8% | 16.4% |
수익률 대 산업: MMSI은 지난 1년 동안 -20.1%의 수익을 기록한 US Medical Equipment 산업보다 더 좋은 성과를 냈습니다.
수익률 대 시장: MMSI은 지난 1년 동안 17.3%를 기록한 US 시장보다 저조한 성과를 냈습니다.
주가 변동성
| MMSI volatility | |
|---|---|
| MMSI Average Weekly Movement | 5.2% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
안정적인 주가: MMSI는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: MMSI의 주간 변동성(5%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1987 | 7,500 | Martha Aronson | www.merit.com |
는 미국, 중국, 일본, 독일, 프랑스, 영국 및 전 세계에서 중재, 진단 및 치료 절차를 위한 일회용 의료 제품을 설계, 개발, 제조 및 판매하는 회사입니다. 이 회사는 심혈관 및 내시경의 두 가지 부문으로 운영됩니다. 이 회사는 미세 천자 키트, 혈관 조영 바늘, 칼집, 가이드 와이어 및 안전 제품, 혈관 조영, 배액, 전달 시스템 및 색전 치료 제품으로 구성된 말초 중재 제품, 연조직 생검 제품 및 액세서리와 같은 종양학 제품을 제공합니다; 심장 접근, 혈관 조영, 전기 생리학 및 심장 리듬 관리, 체액 관리, 혈역학 모니터링, 지혈 및 중재 제품으로 구성된 심장 중재 제품; 척추 확대, 고주파 절제 및 뼈 생검 시스템을 포함한 척추 제품.
Merit Medical Systems, Inc. 기초 지표 요약
| MMSI 기초 통계 | |
|---|---|
| 시가총액 | US$4.38b |
| 순이익 (TTM) | US$139.34m |
| 매출 (TTM) | US$1.54b |
31.3x
주가수익비율(P/E)2.8x
주가매출비율(P/S)MMSI는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| MMSI 손익계산서 (TTM) | |
|---|---|
| 매출 | US$1.54b |
| 매출원가 | US$791.39m |
| 총이익 | US$751.05m |
| 기타 비용 | US$611.71m |
| 순이익 | US$139.34m |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
Jul 30, 2026
| 주당순이익(EPS) | 2.34 |
| 총이익률 | 48.69% |
| 순이익률 | 9.03% |
| 부채/자본 비율 | 45.2% |
MMSI의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/07/22 02:16 |
| 종가 | 2026/07/22 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Merit Medical Systems, Inc.는 22명의 분석가가 다루고 있습니다. 이 중 10명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| null null | Baird |
| David Rescott | Baird |
| Michael Petusky | Barrington Research Associates, Inc. |